These ITP‐experienced physicians mostly initiated TPO‐RAs and anti‐CD20 for patients with persistent or chronic disease needing treatment and for those experiencing a second or third relapse (third or fourth episode of ITP). This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.